Achieve has late-stage cytisinicline data, an accepted smoking-cessation NDA, and a fresh financing. The catch is that management now expects a manufacturing-driven FDA Complete Response Letter before any U.S. launch.
Paid login unlocks company financials, filing timeline, peer comparison, scorecard, and discussion. Valuation remains admin-only while we finalize market-data licensing.
